A Study of LY4060874 in Healthy Participants
Completed · Phase 1 · NCT06709820
Conditions: Healthy Participants
At a glance
- Research payments reported, 2025
- $1.5M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 121
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY4060874 (drug), LY4060874 (drug), Placebo (drug), Placebo (drug)
- Dates
- Started 2024-12-02; completion 2026-02-20
- Results posted
- Not yet
The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants. Study participation may last up to 22 weeks and up to approximately 18 study visits.
From ClinicalTrials.gov, last updated 2026-04-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $1.5M in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research LP Dallas $1.5M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.